{"id":"W4379282697","doi":"10.1200/jco.2023.41.16_suppl.4008","title":"Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Medicine; Cohort; Internal medicine; Biliary tract cancer; Gemcitabine; Gallbladder cancer; Oncology; Clinical endpoint; Cancer; Metastatic breast cancer; Gastroenterology; Response Evaluation Criteria in Solid Tumors; Breast cancer; Trastuzumab; Surgery; Phases of clinical research; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004373642,0.000289817,0.002067481,0.0001595413,0.0001023389,0.00002593018,0.0004174106,0.0003509492,0.0001689564],"category_scores_gemma":[0.004889819,0.0001725308,0.0005573769,0.0006531551,0.0002606368,0.0001434774,0.0001771229,0.001780085,0.00005470603],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002789621,"about_ca_system_score_gemma":0.001481207,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002877066,"about_ca_topic_score_gemma":0.00541615,"domain_scores_codex":[0.9942122,0.0009303953,0.003276055,0.0004963293,0.0005909185,0.000494167],"domain_scores_gemma":[0.9912201,0.006174969,0.001428909,0.000536977,0.0002910022,0.0003480257],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02497765,0.009100222,0.7174847,0.00002451396,0.001448611,0.006573389,0.003425412,0.00001852936,0.0003011437,0.000002525519,0.08671919,0.1499241],"study_design_scores_gemma":[0.04026111,0.01395033,0.901994,0.0002117902,0.0007766047,0.00009103628,0.002599926,0.00007440496,0.00003398554,0.00005837979,0.03978296,0.0001654124],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9711639,0.002016066,0.000002794951,0.02313497,0.001819764,0.0007989327,0.0001450284,0.00004352102,0.000875082],"genre_scores_gemma":[0.9912484,0.00335183,0.00007172529,0.00204966,0.002747908,0.00003822041,0.00004629726,0.0000378574,0.0004081239],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1845094,"threshold_uncertainty_score":0.7733684,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2021545997385521,"score_gpt":0.4946438982538278,"score_spread":0.2924892985152757,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}